March 2020

The opioids crisis was a key talking point in 2019. With high-profile legal battles putting the pharma industry under a spotlight, the ongoing fallout from the scandal has left a deep dent in both the finances and reputations of many pharma companies. But how will the industry address the epidemic moving forward? We find out.

Plus, we examine two concepts that could bridge the gap between precision medicine and blanket drug development, take a look at the first recyclable unit dose packaging, and explore the benefits of Trikafta the world’s first triple combination therapy for cystic fibrosis.

Also, we find out about innovation in the cannabinoid industry, talk to Cidara about resistance to anti-fungal medications, investigate pharma’s attitude to whistleblowers and data leaks, and find out what is causing medication shortages around the world.


Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor | Daniel Garrun

Writers | Allie Nawrat, Abi Millar, Chris Lo, Frits Stulp, Natalie Healey
Magazine Designer | Marzia Del Gaone

Graphic Designers | Filipe Costa, Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West


Sales Manager | Nimai Amin

+44 (0) 207 936 6453


For media partnership enquiries please contact our publishing assistant: Sophie Hoare

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.